Livin/ML-IAP as a new target for cancer treatment.
Livin is a member of the inhibitors of apoptosis protein (IAP) gene family, which encodes negative regulatory proteins that prevent cell apoptosis. Livin is selectively expressed in the most common human neoplasms and appears to be involved in tumor cell resistance to chemotherapeutic agents. Several studies in vitro and in vivo have demonstrated that down-regulation of Livin expression increases the apoptotic rate, reduces tumor growth potential and sensitized tumor cells to chemotherapeutic drugs. This review will focus on the role of this protein during cancer development and progression and will demonstrate possible targets for cancer therapy.
Liu
Bin
B
Hebei Laboratory of Medical Biotechnology, Institute of Basic Medical Science, Hebei Medical University, Shijiazhuang 050017, PR China.
Han
Mei
M
Wen
Jin-Kun
JK
Wang
Ling
L
D048868:Adaptor Proteins, Signal Transducing / Q000187:drug effects* / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000187:drug effects* / Q000378:metabolism; D009363:Neoplasm Proteins / Q000187:drug effects* / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D048868:Adaptor Proteins, Signal Transducing; D000970:Antineoplastic Agents; C419866:BIRC7 protein, human; D051034:Inhibitor of Apoptosis Proteins; D009363:Neoplasm Proteins